An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

@article{Levie2008AnAL,
  title={An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.},
  author={Karin Levie and Isabel Leroux-Roels and Karel P M Hoppenbrouwers and Anne-Diane Kervyn and Corinne Vandermeulen and Sheron Forgus and Geert Leroux-Roels and Sylvie Pichon and Inca C. Kusters},
  journal={The Journal of infectious diseases},
  year={2008},
  volume={198 5},
  pages={642-9}
}
BACKGROUND To protect a naive global population against pandemic influenza, pandemic vaccines should be effective at low antigen doses, because of limited manufacturing capacity. METHODS In a multicenter, randomized, blind-observer phase 1 trial, groups of 50 healthy young adults received 2 doses, 21 days apart, of influenza A/Vietnam/1194/2004 NIBRG-14 (H5N1) vaccine containing 1.9, 3.8, 7.5 or 15 microg of hemagglutinin with oil-in-water emulsion adjuvant or 7.5 microg of hemagglutinin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

and Drug Administration

  • US Foo
  • Guidance for industry: clinical data needed to…
  • 2007

confers superior immunogenicity in adult subjects ( 18 – 60 years of age ) with chronic diseases who are at risk of post - influenza complications

  • RL Atmar, WA Keitel, SM Patel
  • 2007

Similar Papers

Loading similar papers…